Pharvaris (NASDAQ:PHVS) Hits New 52-Week Low – Time to Sell?

Pharvaris (NASDAQ:PHVS)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $14.00 and last traded at $14.85, with a volume of 294 shares trading hands. The stock had previously closed at $14.95.

Wall Street Analysts Forecast Growth

Separately, JMP Securities boosted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Down 2.3 %

The firm has a 50-day moving average price of $16.31 and a two-hundred day moving average price of $18.73. The firm has a market cap of $746.70 million, a PE ratio of -5.10 and a beta of -2.84.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently modified their holdings of PHVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pharvaris by 30.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock worth $1,222,000 after acquiring an additional 14,838 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $853,000. Soleus Capital Management L.P. lifted its position in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after buying an additional 216,483 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Pharvaris during the fourth quarter worth $152,000. Finally, Octagon Capital Advisors LP grew its holdings in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after buying an additional 157,530 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.